Deciphera Pharmaceuticals LLC (DCPH)vsViatris Inc (VTRS)
DCPH
Deciphera Pharmaceuticals LLC
$25.59
0.00%
HEALTHCARE · Cap: $2.21B
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 8076% more annual revenue ($14.30B vs $174.91M). VTRS leads profitability with a -24.6% profit margin vs -108.9%. VTRS earns a higher WallStSmart Score of 50/100 (C-).
DCPH
Avoid30
out of 100
Grade: F
VTRS
Buy50
out of 100
Grade: C-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.5% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
ROE of -50.4% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : DCPH
The strongest argument for DCPH centers on Revenue Growth. Revenue growth of 34.5% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : DCPH
The primary concerns for DCPH are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
DCPH profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
DCPH is growing revenue faster at 34.5% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Deciphera Pharmaceuticals LLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to improve the lives of cancer patients by addressing key drug resistance mechanisms that limit the rate and durability of response to existing cancer therapies. The company is headquartered in Waltham, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?